Progression-Free Survival Ratio As End Point for Phase II Trials in Advanced Solid Tumors

被引：31

作者：

Buyse, Marc ^{[1
]}

Quinaux, Emmanuel ^{[1
]}

Hendlisz, Alain ^{[2
]}

Golfinopoulos, Vassilis ^{[2
]}

Tournigand, Christophe ^{[3
]}

Mick, Rosemarie ^{[4
]}

机构：

[1] Int Inst Drug Dev, Louvain, Belgium

[2] Inst Jules Bordet, B-1000 Brussels, Belgium

[3] Hop St Antoine, F-75571 Paris, France

[4] Univ Penn, Philadelphia, PA 19104 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期

关键词：

GASTROINTESTINAL STROMAL TUMORS; COLORECTAL-CANCER; ANTICANCER AGENTS; DESIGN; 5-FLUOROURACIL; OXALIPLATIN; IMATINIB; SIZE; TIME;

D O I：

10.1200/JCO.2010.34.0380

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：E451 / E452

页数：2

共 11 条

[1]

Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma [J].

Bonetti, A ;

Zaninelli, M ;

Leone, R ;

Franceschi, T ;

Fraccon, AP ;

Pasini, F ;

Sabbioni, R ;

Cetto, GL ;

Sich, D ;

Brienza, S ;

Howell, SB .

ANNALS OF ONCOLOGY, 2001, 12 (02) :187-191

[2]

On the Use of Change in Tumor Size to Predict Survival in Clinical Oncology Studies: Toward a New Paradigm to Design and Evaluate Phase II Studies [J].

Bruno, R. ;

Claret, L. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (02) :136-138

[3]

Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients [J].

Comella, P ;

Casaretti, R ;

Crucitta, E ;

De Vita, F ;

Palmeri, S ;

Avallone, A ;

Orditura, M ;

De Lucia, L ;

Del Prete, S ;

Catalano, G ;

Lorusso, V ;

Comella, G .

BRITISH JOURNAL OF CANCER, 2002, 86 (12) :1871-1875

[4]

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours [J].

Debiec-Rychter, Maria ;

Sciot, Raf ;

Le Cesne, Axel ;

Schlemmer, Marcus ;

Hohenberger, Peter ;

van Oosterom, Allan T. ;

Blay, Jean-Yves ;

Leyvraz, Serge ;

Stul, Michel ;

Casali, Paolo G. ;

Zalcberg, John ;

Verweij, Jaap ;

Van Glabbeke, Martine ;

Hagemeijer, Anne ;

Judson, Ian .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (08) :1093-1103

[5]

Selecting Systemic Cancer Therapy One Patient at a Time: Is There a Role for Molecular Profiling of Individual Patients With Advanced Solid Tumors? [J].

Doroshow, James H. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (33) :4869-4871

[6]

Design of phase II cancer trials using a continuous endpoint of change in tumor size: Application to a study of sorafenib and erlotinib in non-small-cell lung cancer [J].

Karrison, Theodore G. ;

Maitland, Michael L. ;

Stadler, Walter M. ;

Ratain, Mark J. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (19) :1455-1461

[7]

Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint [J].

Mick, R ;

Crowley, JJ ;

Carroll, RJ .

CONTROLLED CLINICAL TRIALS, 2000, 21 (04) :343-359

[8]

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:: A randomized GERCOR study [J].

Tournigand, C ;

André, T ;

Achille, E ;

Lledo, G ;

Flesh, M ;

Mery-Mignard, D ;

Quinaux, E ;

Couteau, C ;

Buyse, M ;

Ganem, G ;

Landi, B ;

Colin, P ;

Louvet, C ;

de Gramont, A .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (02) :229-237

[9]

Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers [J].

Von Hoff, Daniel D. ;

Stephenson, Joseph J., Jr. ;

Rosen, Peter ;

Loesch, David M. ;

Borad, Mitesh J. ;

Anthony, Stephen ;

Jameson, Gayle ;

Brown, Susan ;

Cantafio, Nina ;

Richards, Donald A. ;

Fitch, Tom R. ;

Wasserman, Ernesto ;

Fernandez, Cristian ;

Green, Sylvan ;

Sutherland, William ;

Bittner, Michael ;

Alarcon, Arlet ;

Mallery, David ;

Penny, Robert .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (33) :4877-4882

[10]

Von Hoff DD, 1998, CLIN CANCER RES, V4, P1079

← 1 2 →